Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

Epilepsy Clinical Trial

Official title:

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00319605
• Other study ID #: N01242
• Status: Completed
• Phase: Phase 4
• First received: April 28, 2006
• Last updated: May 24, 2012
• Start date: April 2006
• Est. completion date: July 2006

Study information

• Verified date: May 2012
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Observational

Clinical Trial Summary

Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: July 2006
• Est. primary completion date: July 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria:

• Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• Levetiracetam

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma

Country where clinical trial is conducted

Spain,